

# Supplemental Material

## Conditions When the Parameter $f$ is lose to 1




Fig.3

Fig. 3 Legend

$$\text{Factor } f = \left\{ \frac{z_\alpha \sqrt{2\bar{p}\bar{q}} + z_\beta \sqrt{p_e(1-p_e) + p_c(1-p_c)}}{z_\alpha \sqrt{2\bar{p}_T\bar{q}_T} + z_\beta \sqrt{p_e^T(1-p_e^T) + p_c(1-p_c)}} \frac{1 + \sqrt{1+2w}}{1 + \sqrt{1+2w_T}} \right\}^2 \text{ intervening in the relative}$$

efficiency of the untargeted and targeted designs with regard to number of randomized patients,

$$n/n^T = \left[ \frac{\delta_1}{\gamma\delta_0 + (1-\gamma)\delta_1} \right]^2 f, \text{ with } w \text{ and } w_T \text{ respectively defined by } w = \frac{(\gamma\delta_0 + (1-\gamma)\delta_1)}{(z_\alpha + z_\beta)^2 \bar{p}\bar{q}} \text{ and}$$

$$w_T = \frac{\delta_1}{(z_\alpha + z_\beta)^2 \bar{p}_T\bar{q}_T}. \gamma \text{ is the proportion of R- patients. } p_c \text{ denotes the response probability in control group}$$

and is assumed to be the same for R- and R+ patients. The response probability in the treatment group is  $p_c + \delta_0$  and  $p_c + \delta_1$  for the R- and R+ patients respectively. The response probability  $p_e$  for the experimental treatment group in the untargeted design is a weighted average of  $p_c + \delta_0$  and  $p_c + \delta_1$  with weights  $\gamma$  and  $(1-\gamma)$  respectively. The response probability in the experimental group in the targeted design is  $p_e^T = p_c + \delta_1$ .  $\bar{p} = (p_e + p_c)/2$ ,  $\bar{q} = 1 - \bar{p}$  and  $\bar{p}_T = (p_e^T + p_c)/2$ ,  $\bar{q}_T = 1 - \bar{p}_T$ . The constants  $z_\alpha$  and  $z_\beta$  denote the 100 $\alpha$  and 100 $\beta$  percentiles of the standard normal distribution. The horizontal axis represents the proportion of patients who express the target and are expected to be responsive to the new treatment.

**Case 0: No Treatment effect  
for R- patients**

○ :  $\delta_0 = 0, \delta_1 = 0.2, p_c = 0.1$

× :  $\delta_0 = 0, \delta_1 = 0.4, p_c = 0.1$

+ :  $\delta_0 = 0, \delta_1 = 0.2, p_c = 0.5$

\* :  $\delta_0 = 0, \delta_1 = 0.4, p_c = 0.5$

**Case 1: Treatment effect  
for R- patients is half as large  
as that for R+ patients**

▷ :  $\delta_0 = 0.1, \delta_1 = 0.2, p_c = 0.1$

☆ :  $\delta_0 = 0.2, \delta_1 = 0.4, p_c = 0.1$

□ :  $\delta_0 = 0.1, \delta_1 = 0.2, p_c = 0.5$

--- :  $\delta_0 = 0.2, \delta_1 = 0.4, p_c = 0.5$

## Assay Imprecision

Let  $R$  be a binary indicator of true tumor status;  $R=1$  for  $R^+$  and  $R=0$  for  $R^-$ .

Let  $A$  be a binary indicator of assay result;  $A=1$  for  $R^+$  and  $A=0$  for  $R^-$ .

Let  $\text{Resp}$  denote binary response;  $\text{Resp}=1$  for response and  $\text{Resp}=0$  for no response.

Let  $T$  denote the treatment group;  $T=c$  for control and  $e$  for the experimental treatment.

In the paper we have assumed that

$$\text{Prob}\{\text{Resp}=1 \mid R=0, T=c\} = \text{Prob}\{\text{Resp}=1 \mid R=1, T=c\}.$$

That is, the  $R^-$  and  $R^+$  patients on the control treatment have the same probability of response. Consequently, it is easy to show that

$$\text{Prob}\{\text{Resp}=1 \mid T=c, A=0\} = \text{Prob}\{\text{Resp}=1 \mid T=c, A=1\} = p_c. \quad (\text{A1})$$

$$\begin{aligned} \text{Prob}\{\text{Resp}=1 \mid T=e, A=0\} &= \text{Prob}\{\text{Resp}=1, R=0 \mid T=e, A=0\} + \text{Prob}\{\text{Resp}=1, R=1 \mid T=e, A=0\} \\ &= \text{Prob}\{\text{Resp}=1 \mid T=e, R=0\} * \text{Prob}\{R=0 \mid A=0\} \\ &\quad + \text{Prob}\{\text{Resp}=1 \mid T=e, R=1\} * \text{Prob}\{R=1 \mid A=0\}. \\ &= (p_c + \delta_0) * \text{NPV} + (p_c + \delta_1) (1 - \text{NPV}) \\ &= p_c + \delta_0 * \text{NPV} + \delta_1 * (1 - \text{NPV}) \end{aligned} \quad (\text{A2})$$

Where NPV denotes the negative predictive value of the assay.

Subtracting (A1) from (A2), the treatment effect for assay negative patients is

$$\text{Treatment effect for assay negative patients} = \delta_0 * \text{NPV} + \delta_1 * (1 - \text{NPV}). \quad (\text{A3})$$

The quantity  $\delta_0$  is the treatment effect for  $R^-$  patients. If that is zero, then the treatment effect for assay negative patients is  $\delta_1 * (1 - \text{NPV})$  as indicated in the manuscript.

Similar to the derivation of (A1) and (A2) we can show that:

$$\text{Prob}\{\text{Resp}=1 \mid T=c, A=1\} = p_c$$

and

$$\begin{aligned}\text{Prob}\{\text{Resp}=1 \mid T=e, A=1\} &= \text{Prob}\{\text{Resp}=1 \mid T=e, R=0\} * \text{Prob}\{R=0 \mid A=1\} \\ &\quad + \text{Prob}\{\text{Resp}=1 \mid T=e, R=1\} * \text{Prob}\{R=1 \mid A=1\} \\ &= (p_c + \delta_0) * (1 - \text{PPV}) + (p_c + \delta_1) \text{PPV} \\ &= p_c + \delta_0 * (1 - \text{PPV}) + \delta_1 * \text{PPV}.\end{aligned}$$

Consequently, the treatment effect for assay positive patients is  $\delta_0 * (1 - \text{PPV}) + \delta_1 * \text{PPV}$  which equals  $\delta_1 * \text{PPV}$  when the treatment effect is limited to R+ patients.